Characteristics | Number (%) / Median (range) | ||
---|---|---|---|
Age | 57 (19–86) | ||
FIGO | |||
I | 42 (25%) | ||
II | 10 (5.95%) | ||
III | 103 (61.31%) | ||
IV | 13 (7.74%) | ||
Histology | |||
Serous | 124 (73.81%) | ||
Endometrioid | 18 (10.72%) | ||
Clear cell | 10 (5.95%) | ||
Mucinous | 4 (2.38%) | ||
Nondifferentiated | 4 (2.38%) | ||
Mixed | 8 (4.76%) | ||
Grade | |||
1 | 16 (9.52%) | ||
2 | 35 (20.83%) | ||
3 | 117 (69.65%) | ||
Cytoreduction | |||
R0 | 116 (69.05%) | ||
R1 (≤ 1 cm) | 29 (17.26%) | ||
R2 (> 1 cm) | 23 (13.69%) | ||
Neoadjuvant chemotherapy | 26 (15.48%) | ||
Bevacizumab | 32 (19.05%) | ||
CA-125 before therapy | 229.20 U/ml (3.80–6000 U/ml) | ||
Nadir CA-125 after therapy | 10 U/ml (2.70–35 U/ml) |